#USA #Avid Bioservices #CDMO #Tustin #Dave Stewart

Avid Bioservices Welcomes Dave Stewart as Chief Technology and Transformation Officer

Avid Bioservices, Inc., a leading Contract Development and Manufacturing Organization (CDMO), has recently made a significant announcement: the appointment of Dave Stewart as Chief Technology and Transformation Officer. This newly created role is not just a title; it signifies Avid's commitment to advancing its growth and transformation strategies under the leadership of CEO Kenneth Bilenberg.

A Strategic Move Towards Growth

The creation of this position is an essential part of Avid’s strategy to ensure continuous expansion and to solidify its role as a preferred partner in the biopharmaceutical industry. Kenneth Bilenberg commented, “Avid has made considerable strides in recent years, and for the future, we have chosen to invest deliberately in people, processes, and systems that will fuel our future growth.”

This statement underlines the proactive approach Avid is taking as it seeks to enhance its market position.

One of the key goals for Dave in his new role will be to oversee the integration of technological transformations and processes across Avid’s development and manufacturing network. He aims to modernize operations through digital advancements, automation, and the inclusion of cutting-edge tools, ensuring that the company remains agile, effective, and aligned with client needs.

Enhancing Client Experience

Bilenberg believes that Stewart's extensive industry experience and proven integrity will be instrumental in this journey. “His leadership will support our vision to be the easiest external partner to work with—reliable, predictable, and proactive at every step,” he said. Stewart himself expressed admiration for Avid's strong reputation for quality and dedication to patients, indicating his eagerness to contribute to the company's mission as it navigates this dynamic phase of growth.

Avid's Commitment to Innovation

The establishment of this role reflects Avid’s ongoing commitment to continuous improvement and customer partnerships. The company is poised to sustain its operational flexibility as it enhances capabilities across its facilities. Avid Bioservices specializes in mammalian cell culture and has maintained a flawless track record with the FDA, earning the trust of biopharmaceutical innovators worldwide due to its quality services and adept navigation of complex global regulatory landscapes.

Avid has successfully manufactured over 600 batches, delivered more than 275 commercial batches globally, and supported six commercially approved products. Furthermore, it has undergone ten successful inspections that resulted in pre-approval or pre-licensing by major regulatory bodies.

Looking Ahead

With Stewart leading the technology and transformation initiatives, Avid is set to enhance its service offerings and fortify its partnerships with clients. His leadership is expected to bring new capabilities that will not only meet but exceed the expectations of the biopharmaceutical industry. As the organization continues to evolve, it remains focused on delivering exceptional quality and patient-centric solutions.

Conclusion

Avid Bioservices is entering a new chapter, driven by strategic improvements and a commitment to being the go-to partner in the industry. With Dave Stewart at the helm of technology and transformation, the future looks bright for Avid and its clients.